Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Heart Disease & Cardiovascular — Weekly Report — October 19, 2026

Home/Health Insights/Heart Disease & Cardiovascular — October 19 – October 26, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Heart Disease & Cardiovascular
Updated Monday · November 16, 2026
Heart Disease & Cardiovascular · October 19 – October 26, 2026

Heart Disease & Cardiovascular
Weekly Report

This week's data 114 new clinical trials registered across 10 countries, with 8,829 trials actively recruiting patients worldwide.
Week of October 19 – October 26, 2026
  • 114 new clinical trials registered across 10 countries.
  • 8,829 trials actively recruiting patients worldwide.
  • Notable trial: Long-Term Cardiovascular Impact of ArmoLIPID Cholesterol Plus: An In Silico Study Using Digital Twins (100000 patients).
  • 975 new research papers published.
  • Drug safety: Most reported effect across tracked medications (atorvastatin, lisinopril, metoprolol, amlodipine, warfarin) was Fatigue.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 19 – October 26, 2026
New Trials This Week
114.
registered Oct 19–Oct 26
Recruiting Now
8,829
active trials seeking patients
Countries
10
with active trials this week
Papers Published
975
new studies this week
Phase 3 Trials
0
late-stage trials this week
Fig. 01

Trials by country

Count · October 19 – October 26, 2026
United States
28
China
11
Not specified
10
Belgium
8
United Kingdom
7
Turkey (Türkiye)
6
France
2
Canada
2
Taiwan
2
Egypt
1
0 7 14 21 28
total
Fig. 02

Trials by phase

Distribution · October 19 – October 26, 2026

New clinical trials registered this week for Heart Disease & Cardiovascular. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

114 trials registered for Heart Disease & Cardiovascular. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Mechanisms and Intervention Strategies of Perioperative Glycemic Variability on Postoperative Delirium Heart Disease & Cardiovascular · Fujian Medical University Union Hospital (NCT07893353) Other Recruiting 225 China
02 Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease Heart Disease & Cardiovascular · Xuanwu Hospital, Beijing (NCT07891650) Other Not Yet Recruiting 160 China
03 Optical Coherence Tomography-Assisted Strategy for Interventional Management of Symptomatic Carotid Stenosis (OASIS-C) Heart Disease & Cardiovascular · Beijing Tiantan Hospital (NCT07886775) Other Not Yet Recruiting 100 China
04 Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia Heart Disease & Cardiovascular · Selcuk University (NCT07882069) Other Completed 70 Turkey (Türkiye)
05 Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients Heart Disease & Cardiovascular · Sohag University (NCT07890168) Other Recruiting 400 Egypt
06 Analysis of Electroencephalogram (EEG) Changes in Subacute Stroke Patients Heart Disease & Cardiovascular · Bundang CHA Hospital (NCT07882082) Other Recruiting 200 South Korea
07 RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab Heart Disease & Cardiovascular · The Royal Wolverhampton Hospitals NHS Trust (NCT07891871) Other Not Yet Recruiting 400 N/A
08 The First-in-Human Study of GW906 Injection Heart Disease & Cardiovascular · Shenzhen Salubris Pharmaceuticals Co., Ltd. (NCT07884461) Phase 1 Completed 40 China
09 Prospective Study Protocol for Multiparametric PCCT Assessment of Early Ventricular Outcomes After CABG Heart Disease & Cardiovascular · Xin Lou (NCT07883499) Other Recruiting 150 China
10 Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant Epilepsy Heart Disease & Cardiovascular · Centre Hospitalier Universitaire, Amiens (NCT07888543) Other Recruiting 20 France
11 Fiber Soda on Postprandial Risk Factors Heart Disease & Cardiovascular · Ball State University (NCT07882264) Other Recruiting 20 United States
12 Early Nutrition and Heart Structure and Function in Preterm Infants During the First Year of Life Heart Disease & Cardiovascular · Assiut University (NCT07892209) Other Not Yet Recruiting 117 N/A
13 SAFELY RULING OUT DEEP VEIN THROMBOSIS IN PREGNANCY WITH THE LEFt SCORE AND TRIMESTER-ADJUSTED D-DIMER CUTOFFS (the PREG-DVT Study): A PROSPECTIVE COHORT STUDY. Heart Disease & Cardiovascular · Marc Righini (NCT07884981) Other Not Yet Recruiting 330 Switzerland
14 UULEX Reliability in Individuals With Stroke Heart Disease & Cardiovascular · Karabuk University (NCT07885774) Other Not Yet Recruiting 30 N/A
15 Replacing Spatial Filtering With Deep-learning Noise Reduction Heart Disease & Cardiovascular · Central Hospital, Nancy, France (NCT07888218) Other Not Yet Recruiting 49 France
16 Psychometric Evaluation of the Traditional Chinese Multidimensional Fatigue Inventory in Patients With Heart Failure Heart Disease & Cardiovascular · Kaohsiung Medical University (NCT07886580) Other Not Yet Recruiting 400 N/A
17 EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction) Heart Disease & Cardiovascular · Virginia Commonwealth University (NCT07883512) Phase 2 Not Yet Recruiting 10 United States
18 Ultrasound-Guided Versus Landmark-Guided Pudendal Block for Post-Hemorrhoidectomy Pain Heart Disease & Cardiovascular · Konya City Hospital (NCT07889869) Other Enrolling By Invitation 80 Turkey (Türkiye)
19 Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi) Heart Disease & Cardiovascular · National Heart, Lung, and Blood Institute (NHLBI) (NCT07882173) Phase 2 Not Yet Recruiting 24 United States
20 Right Heart Injury Monitoring on ECMO Heart Disease & Cardiovascular · Papworth Hospital NHS Foundation Trust (NCT07880730) Other Not Yet Recruiting 30 United Kingdom
21 VR During Chest Tube Removal After CABG Heart Disease & Cardiovascular · Maltepe University (NCT07891299) Other Completed 82 Turkey (Türkiye)
22 Prehospital Response and Emergency Stroke Transport Optimisation Heart Disease & Cardiovascular · Xuanwu Hospital, Beijing (NCT07892053) Other Not Yet Recruiting 320 China
23 Comparison of Two Pulse Field Ablation Systems for AF Ablation Heart Disease & Cardiovascular · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (NCT07883629) Other Recruiting 120 United States
24 A First-in-Human Study to Evaluate the Safety and Efficacy of Left Ventricular Assist Device Combined With Exosome Therapy for Patients With Heart Failure(RESTORATION) Heart Disease & Cardiovascular · Yining Yang (NCT07883317) Phase 1 Not Yet Recruiting 24 N/A
25 AI-CLINIC: A Prospective Multisite Feasibility and Safety Study of AI-Assisted Pre-Consultation History-Taking in Outpatient Cardiology Heart Disease & Cardiovascular · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (NCT07883304) Other Not Yet Recruiting 60 N/A
26 Danang Cerebral Venous Thrombosis Registry Heart Disease & Cardiovascular · Da Nang Hospital (NCT07890675) Other Recruiting 110 Vietnam
27 Adapted Group Therapy Compared With Usual Care for Anxiety and Depression in Adults With an Autism Diagnosis Heart Disease & Cardiovascular · Lovisenberg Diakonale Hospital (NCT07880028) Other Not Yet Recruiting 154 N/A
28 Stopping Blood Pressure Medications Without Tapering in Long-Term Care Heart Disease & Cardiovascular · University of Alberta (NCT07890129) Other Completed 11 Canada
29 Preventing Kidney Injury Using Carbon Dioxide as Contrast Medium in Patients With Peripheral Arterial Disease (PAD) and Chronic Kidney Disease (CKD) Having Arterial Intervention Heart Disease & Cardiovascular · University of Leicester (NCT07891988) Other Active Not Recruiting 184 United Kingdom
30 Sequential Digital Intervention to Increase Influenza Vaccination in Patients With Heart Failure Heart Disease & Cardiovascular · Heart Health Research Center (NCT07880158) Other Not Yet Recruiting 588 China
31 Physical Performance and Cognitive Functions in Patients With Chronic Stroke Heart Disease & Cardiovascular · Kutahya Health Sciences University (NCT07887776) Other Completed 66 Turkey (Türkiye)
32 A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant Heart Disease & Cardiovascular · Lumosa Therapeutics Co., Ltd. (NCT07890298) Phase 2 Recruiting 10 Taiwan
33 Evaluation of the Effect of a Low-FODMAP Diet on Gastrointestinal Symptoms and Inflammatory Markers in Fabry Patients Heart Disease & Cardiovascular · Acibadem University (NCT07888998) Other Active Not Recruiting 30 Turkey (Türkiye)
34 Long-Term Cardiovascular Impact of ArmoLIPID Cholesterol Plus: An In Silico Study Using Digital Twins Heart Disease & Cardiovascular · Aeterna Medical Solutions SL (NCT07892092) Other Completed 100,000 Spain
35 Physiology-directed Epinephrine Dosing in Pediatric Cardiac Arrest Heart Disease & Cardiovascular · Children's Hospital of Philadelphia (NCT07890610) Other Recruiting 1,620 United States
36 A Novel Multimodal Approach to Promote Motor Recovery and Plasticity After Stroke Heart Disease & Cardiovascular · University of Utah (NCT07887880) Other Not Yet Recruiting 78 United States
37 Iopidine to Decrease Intraocular Pressure Rise After Injections Heart Disease & Cardiovascular · Retina Consultants of Delmarva (NCT07891910) Phase 4 Not Yet Recruiting 120 United States
38 Factors Influencing Outcomes in ECMO and Impella Patients: Metabolic and Thyroid Hormone Dynamics Heart Disease & Cardiovascular · Gottsegen National Cardiovascular Institute (NCT07885618) Other Recruiting 160 Hungary
39 A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments Heart Disease & Cardiovascular · Pfizer (NCT07881835) Phase 4 Not Yet Recruiting 75 N/A
40 The Development and Optimization of a Cardiac Magnetic Resonance Imaging Protocol in a 3 Tesla Scanner Heart Disease & Cardiovascular · Wang . Jiun-Jie (NCT07889076) Other Completed 120 Taiwan
41 Effects of Tart Cherry and Aronia Extract Supplementation on Selected Physiological Parameters in Endurance-Trained Men Heart Disease & Cardiovascular · Wroclaw Medical University (NCT07885098) Other Not Yet Recruiting 25 Poland
42 AI-ECG Detection of Occlusion Myocardial Infarction at Emergency Department Triage (TRIACS) Heart Disease & Cardiovascular · University Medical Centre Maribor (NCT07882849) Other Not Yet Recruiting 1,000 Slovenia
43 Long-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart Disease Heart Disease & Cardiovascular · Metcela Inc. (NCT07884318) Other Recruiting 40 Japan
44 MCG Algorithm Optimization Study in Patients With Coronary Artery Stenosis Heart Disease & Cardiovascular · AMCG (NCT07888465) Other Not Yet Recruiting 165 N/A
45 Belgo-Luxembourg Leadless PM Registry Heart Disease & Cardiovascular · Universitaire Ziekenhuizen KU Leuven (NCT07879716) Other Not Yet Recruiting 190 Belgium
46 Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills Heart Disease & Cardiovascular · Qilu Hospital of Shandong University (NCT07885462) Phase 4 Not Yet Recruiting 496 China
47 Energy Dose and Cardioversion Outcomes in AF Heart Disease & Cardiovascular · Second Affiliated Hospital, Zhejiang University, School of Medicine (NCT07884253) Other Not Yet Recruiting 400 N/A
48 Validation of Cor-IS Impedance Spectroscopy Against Ultrasound Flow-Mediated Dilation Heart Disease & Cardiovascular · Aristotle University Of Thessaloniki (NCT07882550) Other Completed 208 Greece
49 Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis Obliterans in Diabetic Patients Based on the HAPA Model Heart Disease & Cardiovascular · Second Affiliated Hospital of Nanchang University (NCT07881588) Other Recruiting 154 China
50 Whole-Body Point-of-Care Ultrasound in Older Adults Presenting to the Emergency Department After a Fall Heart Disease & Cardiovascular · Kocaeli City Hospital (NCT07886164) Other Recruiting 105 Turkey (Türkiye)
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Heart Disease & Cardiovascular. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
atorvastatin Fatigue 1,084
lisinopril Fatigue 1,493
metoprolol Fatigue 1,783
amlodipine Fatigue 2,132
warfarin Off Label Use 239

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Heart Disease & Cardiovascular. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

975 papers

Recently published peer-reviewed studies related to Heart Disease & Cardiovascular, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Same Class, Different Risk? Dapagliflozin versus Empagliflozin and Genitourinary Safety in Heart Failure with Preserved Ejection Fraction: A Retrospective Comparative Cohort Study. Danau RA et al. 10.2478/rjim-2026-0024
View abstract

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors are guideline-directed therapy for heart failure with preserved ejection fraction (HFpEF), but comparative genitourinary safety data for dapagliflozin and empagliflozin in HFpEF-treated populations remain limited. OBJECTIVE: To compare 6-month symptomatic urinary tract infection (UTI), asymptomatic bacteriuria, and other genitourinary adverse events among patients newly initiated on dapagliflozin or empagliflozin for HFpEF. METHODS: This retrospective, single-centre comparative cohort study included 239 adults with physician-documented HFpEF retained after a requirement for at least 6 months of continuous follow-up: 113 received dapagliflozin 10 mg once daily and 126 received empagliflozin 10 mg once daily. The original outcome of any documented bacteriuria/UTI was separated into symptomatic UTI and asymptomatic bacteriuria. Risk differences and 95% confidence intervals were calculated; a multivariable logistic model of the original documented bacteriuria/UTI composite adjusted for age, sex, and baseline estimated glomerular filtration rate (eGFR). RESULTS: Any documented bacteriuria/UTI occurred in 21/113 (18.6%) dapagliflozin-treated participants and 25/126 (19.8%) empagliflozin-treated participants. Symptomatic UTI occurred in 4/113 (3.5%) and 5/126 (4.0%), respectively; 17/113 (15.0%) and 20/126 (15.9%) had documented asymptomatic bacteriuria. The risk difference for the composite, calculated as empagliflozin minus dapagliflozin, was 1.3 percentage points (95% CI -8.9 to 11.2). The adjusted odds ratio was 1.62 (95% CI 0.76-3.45; p = 0.208). Other genitourinary events were uncommon and estimates were imprecise. CONCLUSIONS: No statistically detectable between-group difference was found in symptomatic UTI, asymptomatic bacteriuria, or the original composite outcome. Confidence intervals were wide and compatible with clinically meaningful differences in either direction. These exploratory findings require confirmation in prospective multicentre studies with standardized culture ascertainment and complete follow-up.

Romanian journal of internal medicine = Revue roumaine de medecine interne 2026 Oct 26 PubMed
02 Correction to "Fetal Sylvian Fissure Maturation in Congenital Heart Disease and Its Relation to Expected Brain Arterial Oxygen Saturation: A Longitudinal Study". 10.1002/pd.70261 Prenatal diagnosis 2026 Oct 25 PubMed
03 Outcome-specific associations of remnant cholesterol with myocardial infarction and stroke across traditional risk factor burden. Tian R et al. 10.1007/s11239-026-03421-1
View abstract

Remnant cholesterol (RC) is considered a contributor to residual cardiovascular risk, but whether its associations with specific cardiovascular outcomes vary according to the burden of traditional cardiovascular risk factors (CVRFs) remains uncertain. We investigated the associations of RC with myocardial infarction (MI) and stroke in relation to cumulative CVRF burden. We conducted a prospective analysis of 84,806 participants from the Kailuan cohort (baseline 2006) without prior cardiovascular disease. CVRF burden was categorized as 0, 1, 2, or ≥ 3 according to current smoking, overweight (BMI ≥ 24 kg/m²), hypertension, and diabetes. Cox proportional hazards models were used to estimate hazard ratios (HRs) for incident MI and stroke through 2021, and interaction terms were used to assess potential effect modification by CVRF burden. During a median follow-up of 15 years, 1,690 MI and 6,416 stroke events occurred. Compared with the lowest quartile, the highest RC quartile was associated with higher risks of MI (HR, 1.59; 95% CI, 1.37-1.83) and stroke (HR, 1.19; 95% CI, 1.11-1.28). In supplementary subtype analyses, the stroke association was mainly observed for ischemic rather than hemorrhagic stroke. The RC-MI association appeared stronger across higher CVRF-burden categories (highest vs. lowest quartile HRs: 1.16, 1.52, 1.67, and 1.80 for 0, 1, 2, and ≥ 3 CVRFs, respectively), whereas the corresponding stroke association was attenuated (HRs: 1.44, 1.29, 1.21, and 1.03). After noncardiovascular death was treated as a competing event, the stroke interaction was attenuated and no longer statistically significant (P for interaction=0.21). In this large prospective cohort, RC was associated with higher risks of both MI and stroke, with stronger and more consistent associations observed for MI. The pattern of association differed across levels of CVRF burden, suggesting that the clinical interpretation of RC may benefit from outcome-specific and risk-context-specific assessment.

Journal of thrombosis and thrombolysis 2026 Oct 25 PubMed
04 The retrieved venous thrombus as a translational platform: a methodologic roadmap for venous immunothrombosis. Galassi L et al. 10.1007/s11239-026-03420-2
View abstract

Percutaneous mechanical thrombectomy is now widely used for iliofemoral deep vein thrombosis (DVT) and intermediate-risk pulmonary embolism (PE) across several device platforms, and every procedure yields intact human thrombus that is routinely discarded. Whether this material can be developed into a translational resource linking thrombus biology to clinical outcome has not been systematically addressed. A narrative, non-systematic review was performed. PubMed/MEDLINE, Scopus, Web of Science and the Cochrane Library were searched (January 2010 to August 2026) for studies addressing the biology, histopathology and translational analysis of mechanically retrieved venous thrombi, supplemented by reference-list, trial-registry and congress hand-searching. Published venous series remain small and largely confined to descriptive histology, disconnected from longitudinal outcomes. Intra-thrombus biology could address venous-specific questions that peripheral biomarkers and imaging alone cannot: post-thrombotic syndrome, incomplete recanalization, chronic thromboembolic pulmonary hypertension and cancer-associated thrombosis. A device-agnostic framework is proposed, comprising structured intra-procedural sampling at the level of the case rather than the anatomical region, centralized specimen processing under harmonized quality standards, a tiered analytic pipeline anchored on quantitative immunohistochemistry, paired peripheral-biomarker collection, pre-specified hypotheses with feasibility-based sample sizes, and biobank infrastructure embedded in existing trial platforms. The equivalent programme in arterial thrombectomy supplies transferable methodology, subject to explicit boundary conditions. The retrieved venous thrombus is among the more underused translational specimens in vascular medicine. A standardized, registry-embedded characterization framework could accelerate progress toward precision venous thrombosis medicine.

Journal of thrombosis and thrombolysis 2026 Oct 25 PubMed
05 In-Hospital and One-Year Outcomes After Percutaneous Coronary Intervention for Chronic Coronary Occlusion in Octogenarians. Amoey D et al. 10.1007/s40119-026-00485-1
View abstract

INTRODUCTION: Older patients often present with complex coronary artery disease alongside multiple comorbidities. There is limited data on the outcomes of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in octogenarians. We aim to investigate the in-hospital and 1-year outcomes following successful CTO-PCI in octogenarians. METHODS: Consecutive patients who had successful CTO-PCI at a single center between 01.2017 and 12.2022 were divided into two groups: octogenarians (age ≥ 80 and < 90 years, n = 123) and a control group (age < 80 years, n = 612). Periprocedural complications, in-hospital major adverse cardiac and cerebrovascular events (MACCE), and 1-year target lesion failure (TLF) were investigated. RESULTS: Octogenarians had a higher prevalence of arterial hypertension (96.7% vs. 91.2%, p = 0.036), atrial fibrillation (28.5% vs. 12.1%, p < 0.001), and chronic kidney disease (CKD) (34.1% vs. 16.5%, p < 0.001) compared to younger counterparts. The rate of failed CTO recanalization was higher in octogenarians (18.5% vs. 8.2%, p < 0.001). Incidence of in-hospital MACCE and periprocedural complications was comparable between the study groups, except for a numerically higher in-hospital mortality in octogenarians (2.4% vs. 0.8%, p = 0.114), and a higher incidence of contrast-induced nephropathy (CIN) (11.4% vs. 4.9%, p = 0.006). At 1 year, TLF did not differ significantly between the study arms (16.2% vs. 12.3%, aHR 1.52; CI 0.81-2.84, p = 0.191). Notably, higher cardiac mortality rates were observed in the octogenarian arm (7.6% vs. 2.7%, HR 2.82; CI 1.13-7.08, p = 0.027). CONCLUSION: Despite numerically higher in-hospital mortality in octogenarians, CTO-PCI in those patients was performed with comparable periprocedural, and acute adverse outcomes, as well as 1-year TLF, to their younger counterparts. Octogenarians remain inherently at a higher long-term mortality risk. Graphical Abstract available for this article. GOV IDENTIFIER: NCT06957613 (retrospectively registered, 03/05/2025).

Cardiology and therapy 2026 Oct 25 PubMed
06 Analysis of mRNA and microRNA profiles in ischemic cardiomyopathy with LVAD support. Dhar K et al. 10.1007/s11033-026-13007-y
View abstract

BACKGROUND: Cardiac remodeling after myocardial infarction is common, and recovery from end stage ischemic cardiomyopathy (ICM) with left ventricular assist device (LVAD) therapy remains rare. Our goal was to identify micro-RNAs (miRNAs) associated with ICM and to evaluate responses to LVAD therapy to better understand epigenetic mechanisms regulating differential gene expression (DGE). METHODS: RNAs were isolated from human myocardial tissues of ICM (n = 11) pre- and post-LVAD placement, along with non-failing (NF) controls (n = 6). Expressions were quantified by utilizing a targeted cardiac panel for mRNA and the nCounter Human v2 miRNA panel for miRNA. Ingenuity pathway analysis (IPA) was performed with DGE. Targeted gene expression profile was validated by performing mRNA-seq. RESULTS: Compared to NF controls, 33 in pre- and 32 genes in post-LVAD were differentially expressed. IPA of mRNA revealed that signals of inflammatory cytokines and blood pressure disorder were activated in pre-LVAD ICM, and norepinephrine and cells migration were triggered in post-LVAD ICM compared to NF controls. Inflammatory response and apoptosis of cardiomyocytes were inhibited in post compared to pre-LVAD. Relative to NF controls, 195 in pre- and 120 miRNAs in post-LVAD ICM were differentially expressed. IPA of miRNA showed that apoptosis and fibrosis of the heart were stimulated both in pre- and post-LVAD ICM. RNA-seq results validated the targeted gene expression. CONCLUSIONS: In ICM, miRNA expression is linked to apoptosis and fibrosis pathways. These changes persist in post-LVAD therapy and contribute to ongoing changes in mRNA expression associated with Heart failure.

Molecular biology reports 2026 Oct 25 PubMed
07 Fully biodegradable ventricular septal defect occluders: from biomaterials to clinical translation. Yang L et al. 10.1007/s12928-026-01364-1
View abstract

Ventricular septal defect (VSD) is the most prevalent congenital heart disease (CHD), which is approximately 20% of all congenital cardiac defects. Although transcatheter closure of VSD is a favorable alternative to traditional open-heart surgery, conventional nitinol-based occluders carry permanent risks of atrioventricular conduction disturbances, device erosion, and nickel allergy, which precluded regulatory approval in the United States for perimembranous VSD. Fully biodegradable occluders represent an attractive solution, offering equivalent closure efficacy while eliminating the long-term risks due to a permanent metallic implant. Owing to favorable endothelization-degradation kinetics, biocompatibility, and mechanical performance, polydioxanone (PDO) and poly-L-lactic acid (PLLA) have emerged as the superior framework and membrane materials, respectively. Clinical evidence from case series, retrospective cohort studies, and a multicenter randomized controlled trial suggests high procedural success and favorable short- to mid-term safety, with a low incidence of conduction disturbances following biodegradable VSD occluder implantation. In 2022, the National Medical Products Administration (NMPA) of China has granted regulatory approval for the MemoSorb device, which represents the first clinical available fully biodegradable VSD occluder. This review focuses on biomaterials science, structural design principles, preclinical animal studies, and the emerging clinical evidence of fully biodegradable VSD occluder.

Cardiovascular intervention and therapeutics 2026 Oct 25 PubMed
08 Predictors of in-hospital venous thromboembolism in patients undergoing primary total hip arthroplasty. Mastrokostas LE et al. 10.1007/s00590-026-04998-2
View abstract

PURPOSE: This study evaluated the national inpatient incidence, patient characteristics, and independent predictors of VTE following primary THA. METHODS: A retrospective cohort study was performed using the National Inpatient Sample from 2016 to 2022. Adult patients undergoing primary THA were identified using ICD-10 procedure codes. The primary outcome was in-hospital VTE, defined as deep vein thrombosis or pulmonary embolism during the index admission. Survey-weighted analyses were used to generate national estimates, compare baseline characteristics, and identify independent predictors of VTE using multivariable logistic regression. Statistical significance was set at P < 0.05. RESULTS: Among 855,645 weighted inpatient primary THA admissions, 1660 patients developed in-hospital VTE, corresponding to an incidence of 0.19%. Patients with VTE were older (P < 0.001) and more frequently covered by Medicare (P < 0.001), treated at large hospitals (P = 0.009), and treated at urban teaching hospitals (P = 0.013). They also had a greater prevalence of comorbidities, including autoimmune disease, coagulopathy, congestive heart failure, deficiency anemia, peripheral vascular disease, pulmonary circulation disorders, and moderate renal failure (all P < 0.001), as well as chronic pulmonary disease (P = 0.001) and obesity (P = 0.003). On adjusted analysis, the strongest predictors of VTE were paralysis (OR 9.79, P < 0.001), lymphoma (OR 4.35, P = 0.001), other neurologic disorders (OR 4.30, P < 0.001), and pulmonary circulation disorders (OR 3.50, P < 0.001). Additional independent predictors included peripheral vascular disease (OR 2.19, P < 0.001), autoimmune disease (OR 2.01, P < 0.001), congestive heart failure (OR 1.83, P = 0.022), coagulopathy (OR 1.80, P = 0.035), deficiency anemia (OR 1.65, P = 0.002), hypothyroidism (OR 1.45, P = 0.007), and obesity (OR 1.35, P = 0.018). CONCLUSION: In-hospital VTE following primary THA was uncommon but concentrated among medically complex patients. Improved risk stratification may guide perioperative counseling, surveillance, and individualized thromboprophylaxis for higher-risk patients.

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie 2026 Oct 25 PubMed
09 A randomized study comparing plant sterol- and soluble fiber-enriched soymilk with plain soymilk in adults with elevated LDL cholesterol. Buranapin S et al. 10.1007/s00394-026-04138-w
View abstract

BACKGROUND: Lowering low-density lipoprotein cholesterol (LDL-C) is an effective strategy to reduce coronary heart disease risk. Plant sterols/stanols, soluble fiber, and soy protein have each shown LDL-C-lowering effects. This study compared the effects of plant sterol-and soluble fiber-enriched soymilk (SFSM) versus plain soymilk (SM) on LDL-C over 8 weeks. METHODS: A total of 242 adults aged ≥ 18 years with hypercholesterolemia (LDL-C > 130 mg/dL), either untreated or receiving stable lipid-lowering therapy were randomized to receive either plain soymilk (SM; n = 119) or plant sterol- and soluble fiber-enriched soymilk (SFSM; n = 123), with two 180-mL packs consumed daily for 8 weeks. Three participants discontinued the assigned intervention during the study (SM, n = 1; SFSM, n = 2); all three attended the week-2 visit and contributed post-baseline laboratory data, but had no week-8 measurements. Both products provided 5 g soy protein per 180-mL serving; SFSM additionally contained 1 g free plant sterol and 5 g inulin (soluble fiber), with a total dietary fiber content of 5.8 g per serving, corresponding to daily intakes of 2 g free plant sterol and 11.6 g total fiber. Fasting plasma glucose and lipid profiles were measured at baseline and at weeks 2, 4, 6, and 8. Dietary intake and physical activity were monitored throughout the study. The intention-to-treat analysis included all 242 randomized participants. RESULTS: At week 8, SFSM group had a greater reduction in LDL-C than the SM group, with an adjusted between-group treatment effect of 5.5 mg/dL (95% CI 0.6 to 10.4, p = 0.028), favoring SFSM, after adjustment for baseline lipid values. No significant between-group differences were found in fasting plasma glucose, HDL-C, triglycerides, total cholesterol/HDL-C ratio, total energy intake, total fat intake, cholesterol intake, water consumption, or physical activity; however, fiber intake increased significantly more in the SFSM group. CONCLUSIONS: These findings support the LDL-C-lowering benefit of plant sterol-and soluble fiber-enriched soymilk compared with plain soymilk over 8 weeks; however, secondary and subgroup findings should be interpreted cautiously because they were exploratory in nature. Trial registration Clinical Trials Registry Identifier: (NCT02459314) Retrospectively registered on May 15, 2015; first posted June 2, 2015. The study was conducted from April 2013 to April 2014. The original protocol date 22 October 2012 is provided as supplementary material.

European journal of nutrition 2026 Oct 25 PubMed
10 Targeting the epigenetic landscape of ECFCs: a new opportunity to enhance vascular repair. Liu Y et al. 10.1007/s10456-026-10103-2
View abstract

Endothelial colony-forming cells (ECFCs) are endothelial progenitor cells characterized by robust proliferative and vasculogenic capacities, making them promising candidates for therapeutic tissue revascularization. However, the clinical application of ECFCs is hindered by their functional impairment under pathological conditions, such as diabetes and cardiovascular disease. Accumulating evidence indicates that aberrant epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA-mediated regulation, have been implicated in disease-associated ECFC dysfunction. In this review, we summarize current insights into the epigenetic regulation of ECFCs in pathological contexts, discuss epigenetic intervention strategies aimed at restoring ECFC function, and further highlight the therapeutic potential of ECFC-derived extracellular vesicles (EVs) as carriers of epigenetic cargo that promotes vascular repair. Collectively, a deeper understanding of the epigenetic landscape of ECFCs and ECFC-derived EVs may facilitate the development of novel therapeutic approaches for vascular regeneration and accelerate the clinical translation of ECFC- and EV-based therapies.

Angiogenesis 2026 Oct 25 PubMed
11 [The role of clinical inertia in the complex care of patients suffering from heart failure]. Schäffer PP et al. 10.1556/650.2026.33661
View abstract

Inertia refers to a lack of energy or helplessness; in the context of heart failure, clinical inertia can be understood primarily as the failure to initiate or optimize therapies known to reduce morbidity and mortality in patients not on optimized therapy. The aim of this review article is to provide an overview of the most recent guidelines and recommendations relevant to the topic, summarize the available international literature, and present the results of practical interventions that may also be feasibly implemented in Hungary. Heart failure remains a condition with an unfavorable prognosis; however, the use of modern, optimal, comprehensive, guideline-directed medical therapies may confer substantial prognostic benefit. In everyday clinical practice, clinical inertia is one of the main barriers to effective treatment, and the need to address it has also been emphasized in recent position statements of the European Society of Cardiology. The integration of multidisciplinary care, structured patient education, and targeted interventions is of fundamental importance in overcoming clinical inertia, optimizing treatment adherence, and improving long-term outcomes. Close follow-up and rapid up-titration of guideline-directed medical therapy in eligible patients are of particular importance and may significantly reduce the relative risk of heart failure hospitalization and all-cause mortality. The use of telemedicine during follow-up, together with the broader exploitation of digital opportunities, provides contemporary clinicians with a range of new possibilities. Based on real-world data, interventions that favorably influence clinical inertia can also be successfully implemented in Hungary, yielding significant clinical benefit for patients with heart failure. Orv Hetil. 2026; 167(43): 1719-1729.

Orvosi hetilap 2026 Oct 25 PubMed
12 Variation and temporal trends in Medicare Severity Diagnosis Related Group billing for carotid endarterectomy across Vascular Quality Initiative centers. Facciponte DN et al. 10.1016/j.jvs.2026.05.030
View abstract

BACKGROUND: Hospitals use Medicare Severity Diagnosis Related Group (MS-DRG) coding to bill for each admission, with higher payment provided for those with complications or comorbidities (CCs) or major CCs (MCCs). We analyzed variation in MS-DRG coding for carotid endarterectomy (CEA) across Vascular Quality Initiative (VQI) centers to identify opportunities for improvement. METHODS: We matched CEA cases in the VQI registry with Medicare claims data from 2013 through 2023. A multivariable stepwise logistic regression model was created to identify variables associated with CC or MCC billing (with odds ratios [ORs]). We examined variations in CC or MCC billing percentages among centers and applied a multivariable model to compare observed-to-expected (O:E) CC or MCC billing rates to adjust for patient differences. Billing trends over time were analyzed using linear regression. RESULTS: Among 75,064 primary CEA admissions for Medicare beneficiaries, 39.5% were billed with CCs or MCCs (31.1% CCs, 8.4% MCCs) and 60.5% without. Eleven VQI clinical variables that indicated CCs were significantly associated with CC or MCC billing: dialysis dependence (OR, 22.30), postoperative neurological events (OR, 5.25), length of stay >2 days (OR, 4.98), pre-existing heart failure (OR, 4.08), any postoperative complication (OR, 3.70), reoperation (OR, 3.65), preoperative neurological event (OR, 1.70), higher American Society of Anesthesiologists class (OR, 1.50), urgent/emergent procedure (OR, 1.28), postoperative intravenous blood pressure management (OR, 1.27), and institutional transfer (OR, 1.16). Across 371 VQI centers, CC or MCC billing rates varied 5.6-fold, ranging from 15% to 84% of admissions. After risk adjustment, observed-to-expected ratios still demonstrated 4.2-fold variation, from 0.45 to 1.90 across centers. The observed rate of CC or MCC billing increased over time, from 35.5% in 2015 to 46.1% in 2023 (P < .001). In contrast, the expected adjusted rates predicted by the model remained stable (P = .269). A discrete inflection point was identified between 2016 and 2017, after which higher billing rates persisted (P < .001). CONCLUSIONS: Substantial variation exists for MS-DRG billing for CEA across VQI centers. Billing rates for CCs or MCCs increased from 2013 through 2023. These findings suggest potential underbilling at some centers and overbilling at others. Leveraging Medicare-linked VQI registry data and the proposed model could help to improve coding and billing accuracy, optimize reimbursement, and reduce Medicare audit risk.

Journal of vascular surgery 2026 Oct 25 PubMed
13 Continuous Stellate Ganglion Block Bridging to Cardiac Sympathetic Denervation in a Long QT Syndrome Neonate. Meynet P et al. 10.1016/j.jaccas.2026.110888
View abstract

BACKGROUND: Congenital long QT syndrome (LQTS) with neonatal onset carries a high risk of drug-refractory ventricular arrhythmias. Continuous percutaneous left stellate ganglion block (PLSGB) as a bridge to left cardiac sympathetic denervation (LCSD) is unexplored in neonates. CASE SUMMARY: We present a newborn female with in utero onset LQTS, complicated by functional 2:1 atrioventricular block and torsades de pointes (TdP). Despite pacemaker implantation, propranolol, and mexiletine, TdP recurred. At 25 days of life, continuous PLSGB with ropivacaine suppressed TdP. At 4 months, video-assisted thoracoscopic surgery (VATS)-LCSD was performed, with no ventricular arrhythmia recurrence in 24 months. NOVELTY: First reported case of continuous PLSGB in a neonate with LQTS; among the few VATS-LCSD cases under 1 year. TAKE-HOME MESSAGES: Early sympathetic neuromodulation should be considered in high-risk pediatric LQTS when medical therapy fails, as a bridge to LCSD. VATS-LCSD is feasible and safe even under 1 year.

JACC. Case reports 2026 Oct 24 PubMed
14 Artificial Intelligence for Automated Continuous Quantification of Left Ventricular Ejection Fraction From Standard Adult Transthoracic Echocardiography: A Systematic Review. Dembi A et al. 10.7759/cureus.118446
View abstract

Left ventricular ejection fraction (LVEF) guides diagnosis and treatment across cardiovascular disease, but its measurement from transthoracic echocardiography (TTE) is operator-dependent and subject to observer variability. Artificial intelligence (AI) methods that estimate a continuous LVEF value have proliferated. This systematic review aimed to summarise how closely they agree with reference measurements at the group and individual-patient level. Following PRISMA 2020 guidelines and protocol registration on the International Prospective Register of Systematic Reviews (PROSPERO: CRD420261419064), we searched MEDLINE and Embase (via Ovid), Scopus, and IEEE Xplore from January 2015 to 10 September 2026, with forward and backward citation searching, for peer-reviewed journal articles of AI-derived continuous LVEF from standard adult TTE that reported an error or agreement metric against a reference standard. Risk of bias was assessed with a tailored Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Results were summarised as unweighted study-level medians without pooling. We included 108 studies. Most were retrospective (86 of 108), and 34 reported an external or independent test cohort as their main result. EchoNet-Dynamic or CAMUS were used in 54 studies. Systematic bias was small (median absolute bias: 1.5 EF percentage points, interquartile range: 0.5 to 3.4; 68 studies). Typical average error was moderate (median mean absolute error: 4.9 points, 62 studies). The median width of the study-specific 95% limits of agreement was 26 points (interquartile range: 22 to 30; 66 studies). Only 10 of 66 studies (15%) had limits within ±10 points, the usual gap between clinical LVEF decision thresholds. The limits were similarly wide when external results were used wherever available (median width: 26.3 points) and somewhat narrower in studies at low risk of bias (23.6 points). AI methods reproduce reference LVEF with small systematic bias, but individual-patient disagreement in most studies exceeds the difference between clinical LVEF categories and the agreement expected between two expert readers. On current evidence, automated LVEF is better suited to assistive use with expert oversight than to stand-alone measurement, pending prospective, externally validated evaluation.

Cureus 2026 Oct PubMed
15 Hemodynamic and Functional Outcomes of Rate-Adaptive and Physiologic Pacing in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Prana Jagannatha GN et al. 10.1002/joa3.70504
View abstract

BACKGROUND: Exercise intolerance and poor quality of life remain challenges in HFpEF, driven by chronotropic incompetence and left atrial dysfunction. We evaluated whether rate-adaptive/accelerated pacing (RAAP), targeting these mechanisms, improves hemodynamic, functional, and patient-reported outcomes. METHODS: PubMed, Embase, and the Cochrane Library were searched. Outcomes included NT-proBNP, Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, 6-min walk distance (6MWD), E/e', and E/A. Within-group pre-post changes and comparisons with usual care were synthesized separately. Effects are reported as mean differences (MD) or odds ratios (OR) with 95% confidence intervals (CI). RESULTS: Eight reports involving 380 patients were included with myPACE overlap handled by one report per cohort per analysis. Within-group, RAAP was associated with reductions in NT-proBNP (MD -462.58 pg/mL; 95% CI -891.37 to -33.79), E/A (MD -1.01; -1.19 to -0.83), and E/e' (MD -3.18; -5.65 to -0.72), and improvements in 6MWD (MD +74.10 m; 36.34 to 111.86) and MLHFQ score (MD -17.40 points; -33.06 to -1.74). Compared with usual care, associations favored RAAP for NT-proBNP (MD -108.51 pg/mL; -118.31 to -98.70), 6MWD (MD +73.36 m; 32.23 to 114.48), MLHFQ score (MD -16.52 points; -24.15 to -8.89), and AF burden (MD -6.13; -7.88 to -4.37). MACE also favored RAAP in an exploratory analysis (OR 0.47; 0.23 to 0.93), whereas peak VO did not differ significantly. CONCLUSIONS: RAAP was associated with favorable changes in hemodynamic and functional outcomes. These findings support further evaluation of individualized rate modulation in adequately powered randomized trials.

Journal of arrhythmia 2026 Oct PubMed
16 Perioperative Management of Decompensated Peripartum Cardiomyopathy With Severe Left Ventricular Dysfunction: A Case Report. Ramkeesoon R et al. 10.7759/cureus.118447
View abstract

Peripartum cardiomyopathy (PPCM) is a potentially life-threatening cause of heart failure that may be difficult to distinguish from the physiological symptoms of pregnancy. We report the case of a 42-year-old woman at 34 weeks of gestation who presented with progressive dyspnea and was found to have severe global left ventricular systolic dysfunction with an ejection fraction of approximately 20%. Despite initial improvement with diuresis, she developed recurrent acute decompensated heart failure requiring intensive care unit readmission. Point-of-care ultrasonography (POCUS) demonstrated pulmonary congestion and reduced forward flow, with a left ventricular outflow tract velocity-time integral (LVOT VTI) of 10 cm. Following hemodynamic optimization with diuresis and inotropic support, cesarean delivery was performed under general anesthesia with invasive monitoring and titrated vasoactive support. Postoperatively, LVOT VTI increased to 15 cm with corresponding clinical improvement. This case highlights the value of serial hemodynamic assessment, including POCUS, and multidisciplinary perioperative management in severe PPCM with recurrent decompensation.

Cureus 2026 Oct PubMed
17 Community Health Worker Coaching, Food Insecurity, and Physical Activity in the Healthy Food First Trial: A Causal Mediation and Longitudinal Analysis. Anderson RE 3rd et al. 10.1177/15598276261498203
View abstract

To evaluate whether change in food insecurity (ΔFI) mediated the effect of a community health worker (CHW) intervention on physical activity (PA) among food insecure (FI) hypertensive adults, we conducted a secondary analysis of the Healthy Food First randomized clinical trial of food insecure adults with hypertension recruited from 364 North Carolina clinical sites. Participants were randomized to CHW coaching or no coaching within a 2 × 2 × 2 factorial design. FI was measured at baseline and 12 months; total PA (MET-min/week) at 12 and 18 months. Mediation models estimated indirect (ACME), direct (ADE), and total effects (ATE) of CHW assignment on 12-month PA through ΔFI. Generalized estimating equations evaluated repeated PA by CHW assignment. CHW assignment was not associated with PA, and ΔFI did not mediate the relationship. Effects were small (ACME = 16.2; 95% CI -62.6, 121.8; ADE = -214.1; 95% CI -871.7, 484.5; ATE = -197.9; 95% CI -855.6, 500.8 MET-min/week). The proportion mediated was near zero (-8.2%; 95% CI -142%, 124%). GEE analyses similarly showed no association (B = 363.7 MET-min/week; SE = 302.8; P = 0.23). Modest improvements in FI alone may be insufficient to increase PA without additional PA supports. ClinicalTrials.gov Identifier: NCT05048836.

American journal of lifestyle medicine 2026 Oct 23 PubMed
18 Concordance Between Trial Efficacy and Real-World Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. Hassanien A et al. 10.7759/cureus.118487
View abstract

Randomized trials established the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in heart failure with reduced ejection fraction (HFrEF). We assessed whether their effectiveness in routine practice is concordant with trial efficacy, appraising and pooling each evidence stream separately. PubMed/MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched from January 1, 2015 to July 2026 for randomized trials and comparative observational studies of SGLT2 inhibitors vs. placebo or nonuse in adults with left ventricular ejection fraction ≤40% reporting mortality or heart failure hospitalization. Risk of bias was assessed with the Cochrane Risk of Bias 2 and the Newcastle-Ottawa Scale. Adjusted all-cause mortality was pooled by random-effects meta-analysis with the Hartung-Knapp adjustment; other outcomes were synthesized narratively. Trial and observational estimates were never combined, and certainty was graded with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Eleven studies were included (two trials and nine observational). For all-cause mortality, the pooled observational HR (0.75, 95% CI 0.71-0.79; I² = 0%) indicated a larger apparent benefit than the pooled trial estimate (HR 0.87, 0.77-0.98). In one registry, the association attenuated to borderline nonsignificance after adjustment for background therapy. For heart failure hospitalization, a consistent trial benefit (HR 0.69, 0.62-0.78) contrasted with attenuated or null real-world estimates (HR 0.84-1.03). Real-world mortality associations with SGLT2 inhibitors in HFrEF are directionally concordant with trial efficacy, but their larger magnitude most plausibly reflects residual confounding, including co-prescription of other guideline-directed therapy. Real-world hospitalization estimates diverged from trials, likely reflecting outcome ascertainment. With very low-certainty observational evidence, the trial estimate remains the best guide to causal benefit.

Cureus 2026 Oct PubMed
19 Tricuspid Chordae Tendineae Rupture Detected After Repair of a Delayed Traumatic Left Ventricular Aneurysm: A Case Report. Shao H et al. 10.12659/AJCR.954932
View abstract

BACKGROUND Delayed traumatic cardiac rupture complicated by secondary tricuspid chordae tendineae rupture is an exceedingly rare clinical entity. We report this case to describe the temporal sequence of events from blunt myocardial contusion to left ventricular aneurysm formation and rupture, followed by secondary tricuspid chordae tendineae rupture. While the precise mechanism linking these events remains to be determined, we propose a potential pathophysiological connection. CASE REPORT A patient presented with rupture of a posterior left ventricular aneurysm 54 days after a fall from a height. The patient was emergently placed on venoarterial extracorporeal membrane oxygenation (VA-ECMO) for circulatory support and subsequently underwent surgical repair of the aneurysm. Postoperative echocardiography revealed new-onset tricuspid chordae tendineae rupture, prompting elective mechanical tricuspid replacement. Histopathological examination of resected valve tissues revealed chronic degenerative changes. To our knowledge, this is the first report documenting this temporal sequence of delayed left ventricular aneurysm rupture followed by tricuspid chordal rupture after surgical repair. CONCLUSIONS This case highlights the importance of continued clinical and echocardiographic vigilance after severe blunt cardiac injury, particularly for detecting late-emerging structural complications such as aneurysm formation and valvular dysfunction. It also illustrates the potential utility of VA-ECMO as a critical bridging strategy to stabilize patients with traumatic cardiac rupture before surgical repair. The observed temporal association between aneurysm repair and subsequent tricuspid chordal rupture is noted, though the exact causal relationship and underlying mechanism remain uncertain.

The American journal of case reports 2026 Oct 25 PubMed
20 Myocardial infarction detection framework using cardiac motion estimation with deformable registration field. Sasaki R et al. 10.1007/s11548-026-03797-8
View abstract

PURPOSE: Cardiovascular diseases are the leading cause of mortality worldwide. Among them, myocardial infarction (MI), which is characterized by abnormal myocardial motion, remains a critically important condition to detect. Accurate diagnosis of MI requires detailed motion analysis; however, motion-based assessment is time-consuming and imposes a considerable burden on physicians. Moreover, most previous studies have relied on local motion descriptors or limited shape features, resulting in suboptimal detection performance. METHODS: To address these limitations, we propose a deep learning framework, termed MambaMorph-Motion Infarction Detector (MMMID), for myocardial infarction detection from cardiac CT images. The proposed pipeline integrates semantic segmentation, sequential deformable registration using MambaMorph, and a DenseNet-based classification module to effectively leverage rich spatiotemporal myocardial motion information across the cardiac cycle. RESULTS: The proposed method enables accurate tracking of myocardial motion aligned with anatomical structures by associating time-resolved motion fields with corresponding CT volumes. MMMID achieved an accuracy of 91.92% and an AUC of 0.9335 on an in-house cardiac CT dataset. Compared with the CT-only configuration, the integration of sequential motion fields improved recall, suggesting that motion information provides complementary diagnostic cues for myocardial infarction detection rather than replacing anatomical CT information. CONCLUSION: The proposed framework enables myocardial infarction detection by jointly leveraging cardiac anatomy and estimated myocardial motion. Although CT appearance remained a strong source of discriminative information, sequential motion fields contributed complementary functional information, particularly for improving sensitivity to infarction cases. MMMID may serve as a supportive tool for automated cardiac CT analysis and could help reduce the burden of motion-based assessment in clinical workflows.

International journal of computer assisted radiology and surgery 2026 Oct 24 PubMed
21 The ascending aorta and vascular profile in recreational masters runners: a cross-sectional study. Sacharczuk W et al. 10.1007/s00421-026-06471-8
View abstract

PURPOSE: Endurance exercise remodels the large arteries, but whether a recreational training dose is sufficient to induce such remodelling is unclear. Masters recreational runners over 40 years are under-represented in this research. We compared the ascending aortic diameter and vascular profile of these runners with sedentary controls of similar age. METHODS: This cross-sectional study included 42 masters recreational runners (at least 20 km per week for at least one year) and 27 sedentary controls, all over 40 years, free of cardiovascular disease and without bicuspid aortic valve or connective tissue disorder. We measured the ascending aortic diameter and left ventricular function by transthoracic echocardiography, and brachial-ankle pulse wave velocity (baPWV) and the ankle-brachial index (ABI) by oscillometry. Circulating collagen-turnover markers (CTX-I, MMP-2) were assayed. The aortic diameter was compared between groups by regression. RESULTS: The ascending aorta was wider in runners (3.25 vs. 2.90 cm; p = 0.001; Cliff's delta 0.45). The difference persisted after adjustment for age, sex and height (beta 0.31 cm; p = 0.001) and in sensitivity analyses. No aortic diameter reached 4.0 cm; all remained within normal limits. The ABI was higher in runners (1.07 vs. 1.03; p = 0.007), and baPWV did not differ (p = 0.069); both stayed within normal limits. CTX-I and MMP-2 did not differ, and left ventricular function was preserved. CONCLUSION: These findings are consistent with modest, exercise-associated aortic remodelling rather than overt aortopathy in recreational masters runners over 40 years.

European journal of applied physiology 2026 Oct 24 PubMed
22 Comorbidity management in inflammatory rheumatic diseases: a dual-perspective survey of patients and rheumatologists. Bartsch V et al. 10.1186/s13075-026-03924-5
View abstract

BACKGROUND: Comorbidities are major contributors to morbidity and mortality in patients with inflammatory rheumatic diseases (IRDs). We assessed real-world implementation of European Alliance of Associations for Rheumatology (EULAR) points to consider for comorbidity management and perceptions of responsibility. METHODS: We conducted a cross-sectional anonymous online survey among patients with IRDs and rheumatologists in Germany. Two questionnaires assessed demographics, perceived responsibility for comorbidity management, and implementation of preventive measures across five domains: cardiovascular risk, infections, malignancies, depression, and osteoporosis. Responses were analysed using descriptive statistics and group comparisons (chi-square, Fisher's exact, Mann-Whitney U tests). RESULTS: A total of 2,213 patients with IRDs and 140 rheumatologists participated. Patient-reported implementation of comorbidity management in routine care was low across all domains (mean 28.8%). Rheumatologists reported substantially higher implementation than patients across all domains, including blood pressure monitoring (83.6% vs 33.8%) and vaccination checks (77.9% vs 33.2%). Most rheumatologists (69.3%) reported that no structured comorbidity screening was in place. Reported barriers included lack of time (91.4%), unclear responsibilities (48.6%), staff shortages (40.0%), and lack of reimbursement (35.0%). Rheumatologists favoured shared responsibility with general practitioners (GPs) for documentation (61.4%) and screening (48.6%), whereas treatment was more often assigned to GPs alone (60.7%). Patients more frequently assigned primary responsibility to GPs, particularly for cardiovascular risk management (72.6%) and vaccinations (73.8%). CONCLUSIONS: Comorbidity management in IRDs is poorly implemented in routine care, and perceptions of responsibility differ between patients and rheumatologists. Clearer role definitions, stronger guidance from rheumatology organisations, and practical tools are needed to improve implementation.

Arthritis research & therapy 2026 Oct 23 PubMed
23 Prospective multicenter feasibility study of omnipolar near-field peak-frequency mapping for slow-pathway localization in typical atrioventricular nodal re-entrant tachycardia. Giaccardi M et al. 10.1186/s12872-026-06779-5
View abstract

BACKGROUND: Slow-pathway (SP) ablation is the established therapy for atrioventricular nodal re-entrant tachycardia (AVNRT). While conventional anatomical and electrogram-guided approaches are effective, SP localization may be challenging in a subset of procedures. Omnipolar near-field (OTNF) peak frequency (PF) mapping has been proposed as a signal-based approach to support SP localization; however, prospective multicenter data remain limited. METHODS: Fifty consecutive adults with inducible typical AVNRT underwent catheter ablation in three Italian hospitals. High-density right atrial mapping was performed during sinus rhythm using a 16-pole grid catheter (Advisor™ HD Grid) with OTNF on the EnSite X system. PF maps were generated (high-frequency threshold > 250 Hz), and RF applications were delivered to the region of highest PF. Voltage maps were also created to delineate low-voltage bridge (LVB) regions (typically 0.04-2 mV) for retrospective overlap/localization analyses; LVB was not used to select ablation targets. RESULTS: Acute procedural success was achieved in all patients, with no procedural complications. The effective ablation site (junctional beats with subsequent SP modification and/or non-inducibility) corresponded to the highest PF region in 45/50 patients (90%). In a retrospective overlap/localization analysis, the effective site fell within the LVB region in 36/50 patients (72%); concordance between PF-defined and LVB-defined regions at the effective site was observed in 35/50 patients (70%). Mean PF in the SP target region was 424 ± 86 Hz versus 272 ± 57 Hz in surrounding tissue (P < 0.05 on paired testing). Exploratory ROC analysis yielded an AUC of 0.937 with an optimal cutoff of 357 Hz (sensitivity 0.87; specificity 0.94); these estimates should be interpreted cautiously because PF guided RF target selection (incorporation/target-selection bias). CONCLUSION: In this prospective multicenter cohort, OTNF-derived PF mapping was feasible and reproducibly identified a discrete region used to guide SP ablation in typical AVNRT. ROC-derived thresholds and performance estimates are exploratory and require independent validation in cohorts where ablation targets are not selected using PF criteria.

BMC cardiovascular disorders 2026 Oct 19 PubMed
24 Sodium-Glucose Cotransporter-2 Inhibitor Use in Kidney Transplant Recipients With Post-Transplantation Diabetes Mellitus - A Cross-Sectional Study. Hoven A et al. 10.1016/j.transproceed.2026.09.025
View abstract

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have proved beneficial effects on cardiovascular risk and preservation of renal function in patients with diabetes mellitus and chronic kidney disease, in addition to their glucose-lowering effects. This study aims to investigate whether SGLT2i was associated with a more favorable metabolic profile in kidney transplant recipients with post-transplantation diabetes mellitus (PTDM). METHODS: In this observational study, patients receiving a kidney transplant between 2007 and 2021 in Norway were identified from the national transplant database. Patients who developed PTDM were identified through new- onset prescription of glucose- lowering treatment after kidney transplantation registered in Norwegian Prescription Database. PTDM patients were categorized whether glucose- lowering treatment included SGLT2i or not during the first 4 years after transplantation. Metabolic parameters at 5 years after transplantation reported to the Norwegian Renal Registry was compared in the 2 patient groups. RESULTS: This observational study included 232 kidney transplant recipients with PTDM. Metabolic parameters at 5 years post-transplantation were compared among the SGLT2i-group (n = 39) and the control group (n = 193); median BMI (27.5 vs. 26.5 kg/m, p = .22), diastolic blood pressure (80 vs. 79 mm Hg, p = .40), systolic blood pressure (129 vs. 132 mm Hg, p = .42), proteinuria-parameters (u-ACR 4.5 vs. 3.5 mg/mmol, p = .33), (u-PCR 26 vs. 13 mg/mmol, p = .29), HbA1c (52 vs. 49 mmol/mol, p = .11) and estimated glomerular filtration rate (eGFR, 61 vs. 56 mL/min/1.73m, p = .20). CONCLUSION: Our study could not demonstrate improved metabolic parameters in PTDM patients treated with SGLT2-inhibitors at 5 years post transplantation.

Transplantation proceedings 2026 Oct 24 PubMed
25 Trends in metabolic risk factor control and medication use among adults with type 2 diabetes in Taiwan, 2015-2024. Li PL et al. 10.1016/j.jfma.2026.10.030
View abstract

BACKGROUND: To evaluate 10-year trends in metabolic control and guideline-directed pharmacotherapy among adults with type 2 diabetes in Taiwan. METHODS: Using Taiwan's National Health Insurance Research Database (2015-2024), we analyzed annual trends in glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and medication use. Blood pressure (BP) was assessed via a nationwide Pay-for-Performance registry. Trends were evaluated overall and across subgroups with cardiovascular disease (CVD) or chronic kidney disease (CKD). RESULTS: The treated population expanded from 1.58 to 2.27 million. Target achievement improved significantly: HbA1c <7.0% rose from 42.5% to 55.3%, and LDL-C <100 mg/dL from 54.3% to 69.0% (both p-trend <0.001). Among patients with all three measurements available, triple-factor control reached 18.2% by 2024. These gains coincided with rapid sodium-glucose cotransporter-2 inhibitor (SGLT2i) uptake (from 3.3% in 2016 to 38.0% in 2024) and increased statin use. However, 23.5% of young adults (20-44 years) maintained poor glycemic control (HbA1c ≥ 8.5%). SGLT2i use was higher in patients with CVD (43.1%) or CKD (43.8%) than in those without the respective conditions (34.7% and 36.6%), while glucagon-like peptide-1 receptor agonist (GLP-1RA) use remained below 4%. CONCLUSIONS: Metabolic control in Taiwan improved substantially alongside adoption of newer therapies. Gaps among younger adults and high-risk cohorts highlight the need for targeted, risk-stratified management.

Journal of the Formosan Medical Association = Taiwan yi zhi 2026 Oct 24 PubMed
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Heart Disease & Cardiovascular
  • Week: October 19 – October 26, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 6:41 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —